These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38346600)

  • 41. The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.
    Dahan A; Beig A; Ioffe-Dahan V; Agbaria R; Miller JM
    AAPS J; 2013 Apr; 15(2):347-53. PubMed ID: 23242514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio.
    Rinaki E; Valsami G; Macheras P
    Pharm Res; 2003 Dec; 20(12):1917-25. PubMed ID: 14725354
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Triple Strategies to Improve Oral Bioavailability by Fabricating Coamorphous Forms of Ursolic Acid with Piperine: Enhancing Water-Solubility, Permeability, and Inhibiting Cytochrome P450 Isozymes.
    Yu D; Kan Z; Shan F; Zang J; Zhou J
    Mol Pharm; 2020 Dec; 17(12):4443-4462. PubMed ID: 32926628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of captisol (SBE7-β-CD) in oral solubility-enabling formulations: Comparison to HPβCD and the solubility-permeability interplay.
    Beig A; Agbaria R; Dahan A
    Eur J Pharm Sci; 2015 Sep; 77():73-8. PubMed ID: 26006306
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements.
    Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Semsey S; Molnár L; Ránky S; Filipcsei G; Heltovics G; Glavinas H
    Int J Pharm; 2017 Oct; 532(1):427-434. PubMed ID: 28919099
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S; Reddy VA; Arora S; Patel K
    Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of humic acid on oral drug delivery of an antiepileptic drug.
    Mirza MA; Agarwal SP; Rahman MA; Rauf A; Ahmad N; Alam A; Iqbal Z
    Drug Dev Ind Pharm; 2011 Mar; 37(3):310-9. PubMed ID: 20815797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.
    Takano R; Sugano K; Higashida A; Hayashi Y; Machida M; Aso Y; Yamashita S
    Pharm Res; 2006 Jun; 23(6):1144-56. PubMed ID: 16715363
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The ethanol metabolite acetaldehyde increases paracellular drug permeability in vitro and oral bioavailability in vivo.
    Fisher SJ; Swaan PW; Eddington ND
    J Pharmacol Exp Ther; 2010 Jan; 332(1):326-33. PubMed ID: 19820208
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Krishna VM; Kumar VB; Dudhipala N
    Pharm Nanotechnol; 2020; 8(3):207-224. PubMed ID: 32416685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro-in vivo evaluation of supercritical processed solid dispersions: permeability and viability assessment in Caco-2 cells.
    Sethia S; Squillante E
    J Pharm Sci; 2004 Dec; 93(12):2985-93. PubMed ID: 15468328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products.
    Okumu A; DiMaso M; Löbenberg R
    Eur J Pharm Biopharm; 2009 May; 72(1):91-8. PubMed ID: 19056493
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.
    Gao Y; Carr RA; Spence JK; Wang WW; Turner TM; Lipari JM; Miller JM
    Mol Pharm; 2010 Oct; 7(5):1516-26. PubMed ID: 20715778
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
    Wei H; Löbenberg R
    Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability.
    He W; Yang K; Fan L; Lv Y; Jin Z; Zhu S; Qin C; Wang Y; Yin L
    Int J Pharm; 2015 Nov; 495(1):9-18. PubMed ID: 26325310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Application of dissolution/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development.
    Kataoka M; Sugano K; da Costa Mathews C; Wong JW; Jones KL; Masaoka Y; Sakuma S; Yamashita S
    Pharm Res; 2012 Jun; 29(6):1485-94. PubMed ID: 22134778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Evaluation of In Vitro Drug Dissolution of Commercially Available Oral Dosage Forms for Itraconazole in Gastrointestinal Simulator With Biorelevant Media.
    Matsui K; Tsume Y; Amidon GE; Amidon GL
    J Pharm Sci; 2016 Sep; 105(9):2804-2814. PubMed ID: 27020985
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of absorption potential of poorly water-soluble drugs by using the dissolution/permeation system.
    Kataoka M; Yano K; Hamatsu Y; Masaoka Y; Sakuma S; Yamashita S
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1317-24. PubMed ID: 23811221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.